Click to Enlarge

Add To Cart

Ras and Cancer in the 21st Century


Book Series:  A Cold Spring Harbor Perspectives in Medicine Collection
Subject Area(s):  Cell Biology

Edited by Linda Van Aelst, Cold Spring Harbor Laboratory; Julian Downward, The Francis Crick Institute; Frank McCormick, University of California, San Francisco

Due July 2018 • 250 pages (approx.), illustrated, index
Hardcover • $135 94.50
ISBN  978-1-621822-21-9
You save: 30%
You will receive free shipping on this item at checkout.
Free shipping offer applies to direct website purchases by individual U.S. and Canada customers only.

  •     Description    
  •     Contents    

Description

Ras proteins are key molecular switches in cell signaling pathways that, when activated, trigger cell growth and division. Mutations that produce abnormally active Ras proteins are common in human cancers, particularly those of the pancreas, lung, and colon. These cancers can be difficult to treat because Ras oncoproteins have long been considered “undruggable.”

Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine covers the recent progress that has been made in understanding Ras biology, how Ras activation leads to tumorigenesis, and ways in which oncogenic Ras signaling may be targeted therapeutically. The contributors review the biochemical characteristics of the different Ras isoforms (HRAS, KRAS, and NRAS), their main effectors and signaling pathways, and the mutations that lead to their constitutive activation. Recent work showing that some Ras oncoproteins may be effectively inhibited by small molecules is covered, as is work on alternative targets (e.g., enzymes that catalyze posttranslational modifications of Ras) and inhibitors (e.g., nucleic acids).

The authors also discuss how organoids and mouse models are being used to study tumor progression and therapeutic efficacy. This volume is therefore essential reading for all cancer biologists, cell and molecular biologists, and pharmacologists concerned with understanding and treating Ras-driven cancers.

Contents

Preliminary
The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants
Jillian A. Parker and Carla Mattos
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters and Channing J. Der
Ras and MAPK
Neal Rosen
P13K: A Crucial Piece in the RAS Signaling Puzzle
Agata Adelajda Krygowska and Esther Castellano
From Ras to Rap and Back, A Journey of 35 Years
Johannes L. Bos
Targeting Ras with Macromolecules
Dehua Pei, Kuangyu Chen, and Hui Liao
Post-Translational Modifications of RAS Proteins
Ian Ahearn, Mo Zhou, and Mark Philips
Targeting the MAPK Pathway in RAS Mutant Cancers
Sarah G. Hymowitz and Shiva Malek
Ras-Mediated Activation of the Raf Family Kinases
Elizabeth M. Terrell and Deborah K. Morrison
GAP Structure
Klaus Scheffzek
Synthetic Lethal Vulnerabilities in KRAS-mutant Cancers
Andrew J. Aguirre and William C. Hahn
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras
Anica Wandler and Kevin Shannon
The Interdependent Activation of SOS and Ras
Pradeep Bandaru, Yasushi Kondo, and John Kuriyan
Genetically Engineered Mouse Models of K-RAS Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets
Matthias Drosten, Carmen Guerra, and Mariano Barbacid
Kras in Organoids
Derek Cheng and David Tuveson
Ras and the Plasma Membrane: A Complicated Relationship
Yong Zhou, Priyanka Prakash, Alemayehu A. Gorfe, and John F. Hancock
Kras and Tumor Immunity: Friend or Foe?
Jane Cullis, Shipra Das, and Dafna Bar-Sagi
Efforts to Develop KRAS Inhibitors
Matthew Holderfield
Nf1 Therapy
Karen Cichowski
MRAS: A Close but Understudied Member of the Ras family
Lucy C. Young and Pablo Rodriguez-Viciana
Index